Advertisement

AAPS PharmSciTech

, 20:74 | Cite as

Oral Delivery of Methylthioadenosine to the Brain Employing Solid Lipid Nanoparticles: Pharmacokinetic, Behavioral, and Histopathological Evidences

  • Pramod Kumar
  • Gajanand Sharma
  • Varun Gupta
  • Ramanpreet Kaur
  • Kanika Thakur
  • Ruchi Malik
  • Anil Kumar
  • Naveen Kaushal
  • Om Prakash Katare
  • Kaisar RazaEmail author
Research Article Theme: Lipid-Based Drug Delivery Strategies for Oral Drug Delivery
Part of the following topical collections:
  1. Theme: Lipid-Based Drug Delivery Strategies for Oral Drug Delivery

Abstract

The present study aimed to orally deliver methylthioadenosine (MTA) to the brain employing solid lipid nanoparticles (SLNs) for the management of neurological conditions like multiple sclerosis. The stearic acid–based SLNs were below 100 nm with almost neutral zeta potential and offered higher drug entrapment and drug loading. Cuprizone-induced demyelination model in mice was employed to mimic the multiple sclerosis–like conditions. It was observed that the MTA-loaded SLNs were able to maintain the normal metabolism, locomotor activity, motor coordination, balancing, and grip strength of the rodents in substantially superior ways vis-à-vis plain MTA. Histopathological studies of the corpus callosum and its subsequent staining with myelin staining dye luxol fast blue proved the potential of MTA-loaded SLNs in the remyelination of neurons. The pharmacokinetic studies provided the evidences for improved bioavailability and enhanced bioresidence supporting the pharmacodynamic findings. The studies proved that SLN-encapsulated MTA can be substantially delivered to the brain and can effectively remyelinate the neurons. It can reverse the multiple sclerosis–like symptoms in a safer and effective manner, that too by oral route.

KEY WORDS

multiple sclerosis brain delivery lipid-based systems remyelination safety 

Notes

Funding information

The financial support from the Central University of Rajasthan, Bandar Sindri, Distt., Ajmer, India, is duly acknowledged.

Compliance with Ethical Standards

All the animal protocols were duly approved by the Animal Ethics Committee, Panjab University, Chandigarh, and the studies were performed in strict accordance to the guidelines laid by the University in accordance with the apt national regulations.

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Warren S, Warren KG. Multiple sclerosis. Malta: World Health Organization; 2001.Google Scholar
  2. 2.
    Kumar P, Sharma G, Gupta V, Kaur R, Thakur K, Malik R, et al. Preclinical explorative assessment of dimethyl fumarate-based biocompatible nanolipoidal carriers for the management of multiple sclerosis. ACS Chem Neurosci. 2018;9:1152–8.  https://doi.org/10.1021/acschemneuro.7b00519.CrossRefPubMedGoogle Scholar
  3. 3.
    Pandit L, Murthy JMK. Treatment of multiple sclerosis. Ann Indian Acad Neurol. 2011;14:S65–9.CrossRefGoogle Scholar
  4. 4.
    Moreno B, Fernandez-Diez B, Di Penta A, Villoslada P. Preclinical studies of methylthioadenosine for the treatment of multiple sclerosis. Mult Scler. 2010;16:1102–8.  https://doi.org/10.1177/1352458510375968.CrossRefPubMedGoogle Scholar
  5. 5.
    Moreno B, Vila G, Fernandez-Diez B, Vázquez R, Penta A, Errea O, et al. Methylthioadenosine promotes remyelination by inducing oligodendrocyte differentiation. Mult Scler Demyelinating Disord. 2017;2:1–13.  https://doi.org/10.1186/s40893-017-0020-8.CrossRefGoogle Scholar
  6. 6.
    Kumar P, Sharma G, Kumar R, Malik R, Singh B, Katare OP, et al. Stearic acid based, systematically designed oral lipid nanoparticles for enhanced brain delivery of dimethyl fumarate. Nanomedicine (Lond). 2017;12:2607–21.  https://doi.org/10.2217/nnm-2017-0082.CrossRefGoogle Scholar
  7. 7.
    Kumar P, Sharma G, Kumar R, Malik R, Singh B, Katare OP, et al. Vitamin-derived nanolipoidal carriers for brain delivery of dimethyl fumarate: a novel approach with preclinical evidence. ACS Chem Neurosci. 2017;8:1390–6.  https://doi.org/10.1021/acschemneuro.7b00041.CrossRefPubMedGoogle Scholar
  8. 8.
    Kumar P, Sharma G, Kumar R, Malik R, Singh B, Katare OP, et al. Enhanced brain delivery of dimethyl fumarate employing tocopherol-acetate-based nanolipidic carriers: evidence from pharmacokinetic, biodistribution, and cellular uptake studies. ACS Chem Neurosci. 2017;8:860–5.  https://doi.org/10.1021/acschemneuro.6b00428.CrossRefPubMedGoogle Scholar
  9. 9.
    Kumar P, Sharma G, Kumar R, Singh B, Malik R, Katare OP, et al. Promises of a biocompatible nanocarrier in improved brain delivery of quercetin: biochemical, pharmacokinetic and biodistribution evidences. Int J Pharm. 2016;515:307–14.  https://doi.org/10.1016/j.ijpharm.2016.10.024.CrossRefPubMedGoogle Scholar
  10. 10.
    Raza K, Singh B, Lohan S, Sharma G, Negi P, Yachha Y, et al. Nano-lipoidal carriers of tretinoin with enhanced percutaneous absorption, photostability, biocompatibility and anti-psoriatic activity. Int J Pharm. 2013;456:65–72.  https://doi.org/10.1016/j.ijpharm.2013.08.019.CrossRefPubMedGoogle Scholar
  11. 11.
    Raza K, Singh B, Singal P, Wadhwa S, Katare OP. Systematically optimized biocompatible isotretinoin-loaded solid lipid nanoparticles (SLNs) for topical treatment of acne. Colloids Surf B Biointerfaces. 2013;105:67–74.  https://doi.org/10.1016/j.colsurfb.2012.12.043.CrossRefPubMedGoogle Scholar
  12. 12.
    Zhen W, Liu A, Lu J, Zhang W, Tattersall D, Wang J. An alternative cuprizone-induced demyelination and remyelination mouse model. ASN Neuro. 2017;9(4):1759091417725174.  https://doi.org/10.1177/1759091417725174.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Kumar P, Kalonia H, Kumar A. Possible GABAergic mechanism in the neuroprotective effect of gabapentin and lamotrigine against 3-nitropropionic acid induced neurotoxicity. Eur J Pharmacol. 2012;674:265–74.CrossRefGoogle Scholar
  14. 14.
    Tung VW, Burton TJ, Quail SL, Mathews MA, Camp AJ. Motor performance is impaired following vestibular stimulation in ageing mice. Front Aging Neurosci. 2016;8:12.  https://doi.org/10.3389/fnagi.2016.00012.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Franco-Pons N, Torrente M, Colomina MT, Vilella E. Behavioral deficits in the cuprizone-induced murine model of demyelination/remyelination. Toxicol Lett. 2007;169:205–13.CrossRefGoogle Scholar
  16. 16.
    Matsushima GK, Morell P. The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol 2001;11:107–116.Google Scholar
  17. 17.
    Masserini M. Nanoparticles for brain drug delivery. ISRN Biochem. 2013;Article ID 238428, 18 pages.  https://doi.org/10.1155/2013/238428.
  18. 18.
    Kumar M, Sharma G, Kumar R, Singh B, Katare OP, Raza K. Lysine-based C60-fullerene nanoconjugates for monomethyl fumarate delivery: a novel nanomedicine for brain cancer cells. ACS Biomater Sci Eng. 2018;4(6):2134–42.CrossRefGoogle Scholar
  19. 19.
    Raza K, Negi P, Takyar S, Shukla A, Amarji B, Katare OP. Novel dithranol phospholipid microemulsion for topical application: development, characterization and percutaneous absorption studies. J Microencapsul. 2011;28(3):190–9.  https://doi.org/10.3109/02652048.2010.546435.CrossRefPubMedGoogle Scholar
  20. 20.
    Raza K, Kumar P, Kumar N, Malik R. Pharmacokinetics and biodistribution of the nanoparticles. In Advances in nanomedicine for the delivery of therapeutic nucleic acids 2017 (pp. 165–186).Google Scholar
  21. 21.
    Zendedel A, Beyer C, Kipp M. Cuprizone induced demyelination as a tool to study remyelination and axonal protection. J Mol Neurosci. 51:567–72.Google Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2019

Authors and Affiliations

  1. 1.Department of Pharmacy, School of Chemical Sciences and PharmacyCentral University of RajasthanAjmerIndia
  2. 2.Department of Pharmaceutical AnalysisNational Institute of Pharmaceutical Education and Research (NIPER)GuwahatiIndia
  3. 3.Division of Pharmaceutics, University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Studies (UGC-CAS)Panjab UniversityChandigarhIndia
  4. 4.Division of Pharmacology, University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Studies (UGC-CAS)Panjab UniversityChandigarhIndia
  5. 5.Department of BiophysicsPanjab UniversityChandigarhIndia

Personalised recommendations